Palvella Therapeutics, Inc. (PVLA) Cash & Current Investments (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Cash & Current Investments for 12 consecutive years, with $14.2 million as the latest value for Q3 2024.
- On a quarterly basis, Cash & Current Investments fell 74.95% to $14.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $14.2 million, a 74.95% decrease, with the full-year FY2023 number at $16.3 million, down 72.42% from a year prior.
- Cash & Current Investments was $14.2 million for Q3 2024 at Palvella Therapeutics, down from $14.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $119.1 million in Q2 2021 to a low of $6.2 million in Q1 2024.
- A 5-year average of $62.4 million and a median of $66.8 million in 2021 define the central range for Cash & Current Investments.
- Peak YoY movement for Cash & Current Investments: skyrocketed 100.07% in 2022, then crashed 89.05% in 2024.
- Palvella Therapeutics' Cash & Current Investments stood at $70.4 million in 2020, then surged by 67.19% to $117.8 million in 2021, then tumbled by 49.76% to $59.2 million in 2022, then tumbled by 72.42% to $16.3 million in 2023, then fell by 12.95% to $14.2 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Cash & Current Investments are $14.2 million (Q3 2024), $14.5 million (Q2 2024), and $6.2 million (Q1 2024).